Beyond Insulin: Novel Approaches to Treating Type 1 Diabetes

Abstract

Get full access to this article

View all access options for this article.

References

Chen

Fan

Wang

et al . The efficacy and safety of SGLT2 inhibitors for adjunctive treatment of type 1 diabetes: a systematic review and meta-analysis. Sci Rep. 2017;7:44128.

Cherney

Perkins

Soleymanlou

et al . Renal hemo-dynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus. Circulation. 2013;129:587-597.

Dejgaard

Knop

Tarnow

et al . Efficacy and safety of the glucagon-like peptide-1 receptor agonist liraglutide added to insulin therapy in poorly regulated patients with type 1 diabetes—a protocol for a randomised, double-blind, placebo-controlled study: the Lira-1 study. BMJ Open. 2015;5(4):e007791.

FDA Drug Safety and Availability page. 2015. FDA drug safety communication: FDA revises labels of SGLT2 inhibitors for diabetes to include warnings about too much acid in the blood and serious urinary tract infections. https://www.fda.gov/Drugs/DrugSafety/ucm475463.htm. Accessed August 24, 2018.

Filippatos

Panagiotopoulou

Elisaf

. Adverse effects of GLP-1 receptor agonists. RevDeabetStud. 2014;11(3):202-230.

Harris

Boland

Meade

Battise

. Adjunctive therapy for glucose control in patients with type 1 diabetes. Diabetes Metab Syndr Obes. 2018;11:159-173.

Kuhadiya

Dhindsa

Ghanim

et al . Addition of lira-glutide to insulin in patients with type 1 diabetes: a randomized placebo-controlled clinical trial of 12 weeks. Diabetes Care. 2016;39:1027-1035.

Mader

Jensen

Ingwersen

Christiansen

Heller

Pieber

. Pharmacokinetic properties of liraglutide as adjunct to insulin in subjects with type 1 diabetes mellitus. Clin Pharmacokinet. 2016;55(11):1457-1463.

Taylor

Blau

Rother

. SGLT2 inhibitors may predispose to ketoacidosis. J Clin Endo Meta. 2015;100(8):2849-2852.

10.

Varanasi

Bellini

Chaudhuri

et al . Liraglutide as an additional treatment for type 1 diabetes. Eur J Endocrinol. 2011;165:77-84.

11.

Zurek

Urteaga

Yendapally

. A review of the efficacy and safety of sodium-glucose cotransporter 2 inhibitors: a focus on diabetic ketoacidosis. Diabetes Spectr. 2017;30(2):137-142.